Nasus Pharma LTD F-1 registration statements

Nasus Pharma Ltd. filed an F-1 registration statement for the resale of up to 5.39 million ordinary shares by selling shareholders, outlining clinical progress for its intranasal drug candidates and recent financing activities.

Nasus Pharma Ltd., a clinical-stage pharmaceutical company, is launching an initial public offering of 1,250,000 ordinary shares, seeking to raise approximately $9.5 million to advance its intranasal drug pipeline, despite significant accumulated losses and a going concern warning from its auditors.

Nasus Pharma Ltd., a clinical-stage pharmaceutical company, has filed an F-1/A registration statement for an initial public offering of 1.25 million ordinary shares, seeking to raise approximately $9.5 million to fund its intranasal drug development programs, despite reporting substantial accumulated deficits and raising 'substantial doubt' about its ability to continue as a going concern.

Nasus Pharma, a clinical-stage specialty pharmaceutical company, is seeking to raise $9.3 million through an initial public offering to advance its intranasal Epinephrine program, despite significant accumulated losses and ongoing concerns about its ability to continue as a going concern.